A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
Massachusetts General Hospital
City of Hope Medical Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Regimmune Corporation
Children's Oncology Group
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Massachusetts General Hospital
City of Hope Medical Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center